Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01001663
Other study ID # M-20090101
Secondary ID
Status Completed
Phase Phase 4
First received October 16, 2009
Last updated September 5, 2013
Start date September 2009
Est. completion date September 2010

Study information

Verified date September 2013
Source Aarhus University Hospital Skejby
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection AgencyDenmark: The Regional Committee on Biomedical Research Ethics
Study type Interventional

Clinical Trial Summary

Is the FemoSeal® closure device safer and more comfortable than manual compression for femoral artery access closure after coronary angiography?


Description:

Access site complication after coronary angiography is still a challenge in everyday practice. The FemoSeal® closure device has proven very safe as shown in the swedish SCAAR registry. This study is aimed to investigate, in a randomized design, if the FemoSeal® has an advantage in safety and efficacy over manual compression.


Recruitment information / eligibility

Status Completed
Enrollment 1005
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The patient must be at least 18 years old

- Patients undergoing femoral access coronary angiography

- Patient must be competent for providing informed, written consent

- Only 6F sheath

Exclusion Criteria:

- Percutaneous coronary intervention

- Intra coronary measurements (FFR, IVUS, OCT, NIR)

- Groin hematoma before closure

- Pseudoaneurysm or AV fistula

- Significant stenosis of ilial or femoral artery

- Prior peripheral artery surgery

- INR > 3,0

- Platelet count < 120 million per millilitre blood

- Coagulopathy (bleeding disorder)

- Thrombolysis in the last 24h

- Planned heparin infusion after the procedure

- Pregnancy

- Uncontrolled hypertension > 200 mmHg / 110 mmHg

- Femoral access device closure in the last 30 days

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Coronary Angiography Via Femoral Artery Access

Intervention

Device:
FemoSeal®
Closure device for femoral artery access closure
Other:
Manual compression
Conventional manual compression

Locations

Country Name City State
Denmark Aarhus University Hospital Skejby Aarhus N

Sponsors (2)

Lead Sponsor Collaborator
Aarhus University Hospital Skejby Vingmed Danmark A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm. 20 minutes, 1 hour and at discharge, pooled Yes
Secondary Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm. Patient self-measurements. 14 days Yes
Secondary Composite of: major vascular complications necessitating surgical repair, A-V fistulation, pseudoaneurysm needing treatment, major bleeding needing transfusion and infection needing antibiotics . 14 days Yes
Secondary Time to hemostasis, from sheath removal to hemostasis is achieved 14 days Yes
Secondary Time from end of closure procedure to ambulation. 1h bedrest recommended. 14 days Yes
Secondary Device deployment failure 20 minutes Yes
Secondary Time to cessation of continuous minor oozing measured from the end of the closure procedure 14 days Yes
Secondary Need for repeated manual compression after end of the closure procedure 14 days Yes
Secondary Pain and discomfort measured on a numerical pain rating scale (0-10) 20 min Yes
Secondary Vasovagal reaction (clinical signs AND Systolic BP drop of more than 30 mmHg AND/OR pulse drop more than 30 b/min. AND reversible immediately after treatment by atropin, fluids) 20 minutes Yes
Secondary The patient seeking medical assistance for all-cause closure site related symptoms after discharge. 14 days Yes
Secondary Pain and discomfort measured on a numerical pain rating scale (0-10) 1 hour Yes
Secondary Pain and discomfort measured on a numerical pain rating scale (0-10) Discharge Yes
Secondary Pain and discomfort measured on a numerical pain rating scale (0-10) 14 days Yes